Max Healthcare Institute Ltd.
MAXHEALTH · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹541.39.
Piotroski F-score 7/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%14.3%
- ✓Low debt (D/E < 0.5)0.32x
- ✕Positive free cash flow
- ✓Revenue growth > 10%12%
- ✓Earnings growing7%
- ✓Net margin ≥ 10%17.2%
- ✕Current ratio > 1.50.89
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 9.99
- ✓Piotroski ≥ 77/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (17.2%).
- •Financially solid — Altman Z 9.99.
- •High Piotroski quality score (7/9).
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Revenue growing (12% YoY).
Threats
- •Trades ~34% above our estimated fair value.
About Max Healthcare Institute Ltd.
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, gynecology, pediatrics, and nephrology, liver and biliary sciences, gastroenterology and Gi surgery, plastic and reconstructive surgery, and organ transplants, as well as ear, nose, and throat. The company also
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.